FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895926360> ?p ?o ?g. }

• W2895926360 endingPage "252" @default.
• W2895926360 startingPage "242" @default.
• W2895926360 abstract "Recent studies have demonstrated that ivabradine (IVA), is a selective inhibitor of funny current (If) and exerts antiarrhythmic effects in the settings of various diseases such as heart failure and myocardial ischemia. However, little is known regarding the effects of long-term IVA treatment on If current and hyperpolarization-activated cyclic nucleotide gated (HCN) channel overexpression.We investigated both the If current and HCN channel expression in wild-type (WT) mice and transgenic (TG) atrial fibrillation (AF) mice (heart-specific overexpressing of (pro) renin receptor TG mice) and examined the effects of IVA on the If current and HCN channel expression, and whether those effects were sufficient to prevent an AF episode. Compared with WT mice, the If current density (at -170 mV: TG, -39.6 ± 4.6 pA/pF; WT, -26.9 ± 3.0 pA/pF; P < 0.001) and activation kinetics (V1/2 : TG, -109.45 ± 1.35 mV; WT, -128.20 ± 1.65 mV), as well as HCN2 and HCN4 messenger RNA expression and HCN4 protein expression were significantly increased in the atrial myocytes of TG mice. After 4 months of IVA treatment (7 mg/kg per day orally) the effects of IVA on TG AF mice were accompanied by the inhibition of upregulation of HCN2 and HCN4 protein expression in atrial tissue, and then resulted in a uniform If loss of function. Furthermore, we observed that ivabradine significantly decreased the incidence of AF in the TG mice (41.2% in TG mice, 16.7% in TG + IVA mice; P < 0.01).IVA reduced the incidence of AF in mice, and the antiarrhythmic effects of IVA are not limited to heart rate reduction, as they partially counteract HCN overexpression and reverse electrophysiological cardiac remodeling by attenuating If gain-of-function." @default.
• W2895926360 created "2018-10-26" @default.
• W2895926360 creator A5004320397 @default.
• W2895926360 creator A5005962127 @default.
• W2895926360 creator A5042862862 @default.
• W2895926360 creator A5046836572 @default.
• W2895926360 creator A5050852420 @default.
• W2895926360 creator A5055688170 @default.
• W2895926360 creator A5067981602 @default.
• W2895926360 creator A5079524660 @default.
• W2895926360 creator A5087664421 @default.
• W2895926360 date "2018-11-05" @default.
• W2895926360 modified "2023-09-25" @default.
• W2895926360 title "Long‐term treatment with ivabradine in transgenic atrial fibrillation mice counteracts hyperpolarization‐activated cyclic nucleotide gated channel overexpression" @default.
• W2895926360 cites W1884338871 @default.
• W2895926360 cites W1930833808 @default.
• W2895926360 cites W1957026520 @default.
• W2895926360 cites W1966738260 @default.
• W2895926360 cites W1999740862 @default.
• W2895926360 cites W2006915553 @default.
• W2895926360 cites W2012221083 @default.
• W2895926360 cites W2022374494 @default.
• W2895926360 cites W2051514127 @default.
• W2895926360 cites W2066454483 @default.
• W2895926360 cites W2076813032 @default.
• W2895926360 cites W2124266852 @default.
• W2895926360 cites W2135491838 @default.
• W2895926360 cites W2151273294 @default.
• W2895926360 cites W2154948165 @default.
• W2895926360 cites W2158644069 @default.
• W2895926360 cites W2159461724 @default.
• W2895926360 cites W2491103610 @default.
• W2895926360 cites W3004050106 @default.
• W2895926360 doi "https://doi.org/10.1111/jce.13772" @default.
• W2895926360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30302853" @default.
• W2895926360 hasPublicationYear "2018" @default.
• W2895926360 type Work @default.
• W2895926360 sameAs 2895926360 @default.
• W2895926360 citedByCount "7" @default.
• W2895926360 countsByYear W28959263602019 @default.
• W2895926360 countsByYear W28959263602020 @default.
• W2895926360 countsByYear W28959263602021 @default.
• W2895926360 countsByYear W28959263602022 @default.
• W2895926360 countsByYear W28959263602023 @default.
• W2895926360 crossrefType "journal-article" @default.
• W2895926360 hasAuthorship W2895926360A5004320397 @default.
• W2895926360 hasAuthorship W2895926360A5005962127 @default.
• W2895926360 hasAuthorship W2895926360A5042862862 @default.
• W2895926360 hasAuthorship W2895926360A5046836572 @default.
• W2895926360 hasAuthorship W2895926360A5050852420 @default.
• W2895926360 hasAuthorship W2895926360A5055688170 @default.
• W2895926360 hasAuthorship W2895926360A5067981602 @default.
• W2895926360 hasAuthorship W2895926360A5079524660 @default.
• W2895926360 hasAuthorship W2895926360A5087664421 @default.
• W2895926360 hasConcept C102230213 @default.
• W2895926360 hasConcept C104317684 @default.
• W2895926360 hasConcept C126322002 @default.
• W2895926360 hasConcept C127561419 @default.
• W2895926360 hasConcept C131453863 @default.
• W2895926360 hasConcept C134018914 @default.
• W2895926360 hasConcept C141035611 @default.
• W2895926360 hasConcept C170493617 @default.
• W2895926360 hasConcept C178790620 @default.
• W2895926360 hasConcept C185592680 @default.
• W2895926360 hasConcept C2777953023 @default.
• W2895926360 hasConcept C2779161974 @default.
• W2895926360 hasConcept C2779167562 @default.
• W2895926360 hasConcept C2780965148 @default.
• W2895926360 hasConcept C50254741 @default.
• W2895926360 hasConcept C55493867 @default.
• W2895926360 hasConcept C66974803 @default.
• W2895926360 hasConcept C71924100 @default.
• W2895926360 hasConcept C83743174 @default.
• W2895926360 hasConcept C84393581 @default.
• W2895926360 hasConceptScore W2895926360C102230213 @default.
• W2895926360 hasConceptScore W2895926360C104317684 @default.
• W2895926360 hasConceptScore W2895926360C126322002 @default.
• W2895926360 hasConceptScore W2895926360C127561419 @default.
• W2895926360 hasConceptScore W2895926360C131453863 @default.
• W2895926360 hasConceptScore W2895926360C134018914 @default.
• W2895926360 hasConceptScore W2895926360C141035611 @default.
• W2895926360 hasConceptScore W2895926360C170493617 @default.
• W2895926360 hasConceptScore W2895926360C178790620 @default.
• W2895926360 hasConceptScore W2895926360C185592680 @default.
• W2895926360 hasConceptScore W2895926360C2777953023 @default.
• W2895926360 hasConceptScore W2895926360C2779161974 @default.
• W2895926360 hasConceptScore W2895926360C2779167562 @default.
• W2895926360 hasConceptScore W2895926360C2780965148 @default.
• W2895926360 hasConceptScore W2895926360C50254741 @default.
• W2895926360 hasConceptScore W2895926360C55493867 @default.
• W2895926360 hasConceptScore W2895926360C66974803 @default.
• W2895926360 hasConceptScore W2895926360C71924100 @default.
• W2895926360 hasConceptScore W2895926360C83743174 @default.
• W2895926360 hasConceptScore W2895926360C84393581 @default.
• W2895926360 hasIssue "2" @default.
• W2895926360 hasLocation W28959263601 @default.
• W2895926360 hasLocation W28959263602 @default.
• W2895926360 hasOpenAccess W2895926360 @default.

• next